With over 25 years of experience, Nicholette has worked in pharmaceuticals, medical devices, and diagnostics, with a commitment to equitable patient access to innovative treatments. She has worked with precision medicine and health tech startups, biotech and medtech scale-ups, and worked in major pharmaceutical companies including Eli Lilly, Amgen, MSD, and Bayer. Her expertise spans clinical development (Phase 1-3), Health Technology Assessment (HTA) new product planning (NPP), market access, and reimbursement (MSAC & PBAC), and she has successfully led commercial strategy, product development and implementation projects across oncology, rare diseases, infectious diseases, chronic disease, reproductive technologies, and genetics. Her approach is pragmatic and holistic, includes broad and diverse stakeholder engagement, and especially the inclusion of patients and their care givers to guide care. Nicholette is the current Board Chair of Genetic Alliance Australia and is passionate about enabling patient access to new technologies and precision medicine through multi-disciplinary collaboration.

Recently stepping into the role of Program Manager – Advanced Therapies at Children’s Health Queensland (CHQ), Natasha is responsible for leading the development & implementation of the CHQ ACTION Centre’s (Advanced therapies & Clinical Trials InnovatiON) Advanced Therapies program and overseeing the coordination of associated clinical trials. Natasha has a long history within the clinical trial industry, including as a data manager in a Phase 1 unit, site monitor with a CRO, study coordinator, and most recently as the Clinical Research Manager for Oncology at the Queensland Children’s Hospital.